GTx, Inc. (GTXI) Reaches $11.55 After 7.00% Up Move; Bankrate (RATE) Sentiment Is 0.65

November 14, 2017 - By Dolores Ford

Bankrate, Inc. is a publisher, aggregator and distributor of personal finance content on the Internet. The company has market cap of $1.26 billion. The Firm provides clients personal finance editorial content across multiple vertical categories, including mortgages, deposits, credit cards, senior care and other personal finance categories. It currently has negative earnings. The Company’s divisions include Banking, Credit Cards, Senior Care and Other.

The stock of GTx, Inc. (NASDAQ:GTXI) is a huge mover today! About 67,571 shares traded or 171.95% up from the average. GTx, Inc. (NASDAQ:GTXI) has declined 39.61% since November 14, 2016 and is downtrending. It has underperformed by 56.31% the S&P500.The move comes after 7 months positive chart setup for the $248.81M company. It was reported on Nov, 14 by Barchart.com. We have $12.36 PT which if reached, will make NASDAQ:GTXI worth $17.42 million more.

Analysts await GTx, Inc. (NASDAQ:GTXI) to report earnings on November, 16. They expect $-0.28 earnings per share, up 44.00% or $0.22 from last year’s $-0.5 per share. After $-0.40 actual earnings per share reported by GTx, Inc. for the previous quarter, Wall Street now forecasts -30.00% EPS growth.

Among 2 analysts covering GTx (NASDAQ:GTXI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. GTx has $16 highest and $0.50 lowest target. $11.50’s average target is -0.43% below currents $11.55 stock price. GTx had 3 analyst reports since August 10, 2016 according to SRatingsIntel. The stock of GTx, Inc. (NASDAQ:GTXI) has “Hold” rating given on Wednesday, August 10 by Jefferies. Jefferies maintained GTx, Inc. (NASDAQ:GTXI) on Friday, December 9 with “Hold” rating.

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The company has market cap of $248.81 million. The Firm is engaged in the development of selective androgen receptor modulators . It currently has negative earnings. The Company’s lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com